标题
Targeting the ERK Signaling Pathway in Melanoma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 6, Pages 1483
出版商
MDPI AG
发表日期
2019-03-25
DOI
10.3390/ijms20061483
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases
- (2019) Gautham Gampa et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
- (2019) Claudia TROJANIELLO et al. Expert Review of Clinical Pharmacology
- Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
- (2019) Chengqian Yin et al. CELL
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
- (2018) Boaz Mendzelevski et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers
- (2018) Brian R. Untch et al. CANCER RESEARCH
- Roles of UVA radiation and DNA damage responses in melanoma pathogenesis
- (2018) Aiman Q. Khan et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
- Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
- (2018) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- (2018) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
- (2018) Anais Del Curatolo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers
- (2018) Michael Grasso et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ultraviolet radiation-mediated development of cutaneous melanoma: An update
- (2018) Gabriella Emri et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features
- (2018) Maija Kiuru et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2018) Michele Maio et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
- (2018) Lucia Demkova et al. Molecular Cancer
- Trajectories of premalignancy during the journey from melanocyte to melanoma
- (2018) Andrew J. Colebatch et al. PATHOLOGY
- RAS-mediated oncogenic signaling pathways in human malignancies
- (2018) Abdul Q. Khan et al. SEMINARS IN CANCER BIOLOGY
- MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
- (2018) Sobhana Babu Boga et al. ACS Medicinal Chemistry Letters
- Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
- (2018) Oleksii S. Rukhlenko et al. Cell Systems
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
- (2018) Alicja Puszkiel et al. CLINICAL PHARMACOKINETICS
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches
- (2018) Giuseppe Palmieri et al. Current Oncology Reports
- MEK inhibitors for the treatment of NRAS mutant melanoma
- (2018) Saro Sarkisian et al. Drug Design Development and Therapy
- Structural snapshots of RAF kinase interactions
- (2018) Soheila Rezaei Adariani et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
- (2018) Kristen S. Hill et al. MOLECULAR CANCER RESEARCH
- Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases
- (2018) Jonas Leichsenring et al. PATHOLOGY
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
- (2018) James Sun et al. OncoTargets and Therapy
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- MEK inhibitors in oncology: a patent review (2015-Present)
- (2017) Debarshi Kar Mahapatra et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Binimetinib for the treatment of NRAS-mutant melanoma
- (2017) Paola Queirolo et al. Expert Review of Anticancer Therapy
- A compendium of ERK targets
- (2017) Evrim B. Ünal et al. FEBS LETTERS
- A review of binimetinib for the treatment of mutant cutaneous melanoma
- (2017) Peter Koelblinger et al. Future Oncology
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
- (2017) Xian Chan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
- (2017) Nourah Obaid et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma
- (2017) Rachel D. Melamed et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
- (2017) Jonas Cicenas et al. MEDICAL ONCOLOGY
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
- (2017) Chao Yan et al. PHARMACOLOGICAL REVIEWS
- Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling
- (2017) Andrew M. Kidger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations in the promoter of the telomerase geneTERTcontribute to tumorigenesis by a two-step mechanism
- (2017) Kunitoshi Chiba et al. SCIENCE
- Epigenetics of malignant melanoma
- (2017) Bruce Moran et al. SEMINARS IN CANCER BIOLOGY
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
- (2017) Goran Micevic et al. Clinical Epigenetics
- Ral signaling pathway in health and cancer
- (2017) Adel Rezaei Moghadam et al. Cancer Medicine
- A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
- (2017) Benjamin Izar et al. Cancer Medicine
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
- (2017) A. Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers
- (2017) Camille Buffet et al. PLoS One
- Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel
- (2017) Blanca de Unamuno Bustos et al. Scientific Reports
- Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation
- (2016) Michael Grasso et al. ACS Chemical Biology
- Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study
- (2016) GA McArthur et al. ANNALS OF ONCOLOGY
- Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
- (2016) Jasmina Paluncic et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients
- (2016) Dae Won Kim et al. CANCER
- An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
- (2016) Zoi Karoulia et al. CANCER CELL
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Targeting mutant NRAS signaling pathways in melanoma
- (2016) Ha Linh Vu et al. PHARMACOLOGICAL RESEARCH
- Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
- (2016) Maryam Abbaspour Babaei et al. Drug Design Development and Therapy
- Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2016) Ajay Bhargava et al. eLife
- Compromised MAPK signaling in human diseases: an update
- (2015) Eun Kyung Kim et al. ARCHIVES OF TOXICOLOGY
- Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
- (2015) J S L Kloth et al. BRITISH JOURNAL OF CANCER
- B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720
- (2015) Aline I Riechardt et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Treatment of NRAS-Mutant Melanoma
- (2015) Douglas B. Johnson et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Epigenetic regulation in human melanoma: past and future
- (2015) Debina Sarkar et al. Epigenetics
- BRAF and MEK inhibition in melanoma
- (2015) Lesly A Dossett et al. Expert Opinion On Drug Safety
- Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis
- (2015) Yu Sun et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Counterpoint: The “dysplastic” nevus
- (2015) Clay J. Cockerell JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dysplastic nevus: Fact and fiction
- (2015) Cliff O. Rosendahl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Outcome of patients with de novo versus nevus-associated melanoma
- (2015) William M. Lin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
- (2015) Adam A. Friedman et al. PLoS One
- Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
- (2015) Teresa E. Williams et al. ACS Medicinal Chemistry Letters
- Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
- (2015) Severa Bunda et al. Nature Communications
- Low Mutational Burden of Eight Genes Involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 Pathways in Female Genital Tract Primary Melanomas
- (2015) Kalliopi I. Pappa et al. Biomed Research International
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- A highly recurrent RPS27 5’UTR mutation in melanoma
- (2015) Ken Dutton-Regester et al. Oncotarget
- Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
- (2015) Ludovica Ciuffreda et al. NEOPLASIA
- Prognostic and Clinicopathologic Associations ofBRAFMutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study
- (2014) Jin-Woo Hong et al. Annals of Dermatology
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
- (2014) J.-J. Grob et al. ANNALS OF ONCOLOGY
- Updates of reactive oxygen species in melanoma etiology and progression
- (2014) Feng Liu-Smith et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer
- (2014) Matthew J. Sale et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
- (2014) M Holderfield et al. BRITISH JOURNAL OF CANCER
- Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns
- (2014) M.A. Marchetti et al. BRITISH JOURNAL OF DERMATOLOGY
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
- (2014) G. Kim et al. CLINICAL CANCER RESEARCH
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
- (2014) M. S. Carlino et al. CLINICAL CANCER RESEARCH
- Somatic Mutation of GRIN2A in Malignant Melanoma Results in Loss of Tumor Suppressor Activity via Aberrant NMDAR Complex Formation
- (2014) Todd D. Prickett et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Update on primary mucosal melanoma
- (2014) Joselin D. Tacastacas et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- GNAQ and GNA11 mutations in uveal melanoma
- (2014) Alexander N. Shoushtari et al. MELANOMA RESEARCH
- Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
- (2014) Deborah JL Wong et al. Molecular Cancer
- Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.
- (2014) A. El-Khoueiry et al. MOLECULAR CANCER THERAPEUTICS
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
- (2014) Neroshan Thevakumaran et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure
- (2014) SAVERIO CANDIDO et al. ONCOLOGY REPORTS
- Clinical and pathological associations of the activatingRAC1P29S mutation in primary cutaneous melanoma
- (2014) Victoria J. Mar et al. Pigment Cell & Melanoma Research
- The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
- (2014) Makoto Wada et al. PLoS One
- Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation
- (2014) S. Bunda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
- (2014) J. A. Lo et al. SCIENCE
- The Genesis of Tyrosine Phosphorylation
- (2014) T. Hunter Cold Spring Harbor Perspectives in Biology
- Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
- (2014) C. E. Burd et al. Cancer Discovery
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
- (2013) Giusy Gentilcore et al. BMC CANCER
- Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
- (2013) A. Nakamura et al. CANCER RESEARCH
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Landscape of genomic alterations in cervical carcinomas
- (2013) Akinyemi I. Ojesina et al. NATURE
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition
- (2013) X Chen et al. ONCOGENE
- Regulation of Small GTPases by GEFs, GAPs, and GDIs
- (2013) Jacqueline Cherfils et al. PHYSIOLOGICAL REVIEWS
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- NMR-based functional profiling of RASopathies and oncogenic RAS mutations
- (2013) M. J. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Highly Recurrent TERT Promoter Mutations in Human Melanoma
- (2013) F. W. Huang et al. SCIENCE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Clinicopathologic Findings and BRAF Mutation in Cutaneous Melanoma in Young Adults
- (2013) Bruna Estrozi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
- (2012) J. Haroche et al. BLOOD
- The Role of the PI3K-AKT Pathway in Melanoma
- (2012) Michael A. Davies CANCER JOURNAL
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
- (2012) Y. Su et al. CLINICAL CANCER RESEARCH
- Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
- (2012) G. Ambrosini et al. CLINICAL CANCER RESEARCH
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- The Ras protein superfamily: Evolutionary tree and role of conserved amino acids
- (2012) Ana Maria Rojas et al. JOURNAL OF CELL BIOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- The dysplastic nevus: From historical perspective to management in the modern era
- (2012) Keith Duffy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
- (2012) Christine M. Lovly et al. PLoS One
- Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
- (2012) Hubing Shi et al. Cancer Discovery
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
- (2011) Peter D. Boasberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genetic alterations of PTEN in human melanoma
- (2011) Almass-Houd Aguissa-Touré et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
- (2011) Sergey I Nikolaev et al. NATURE GENETICS
- Exome sequencing identifies GRIN2A as frequently mutated in melanoma
- (2011) Xiaomu Wei et al. NATURE GENETICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
- (2011) Hiroyuki Abe et al. ACS Medicinal Chemistry Letters
- Recurrent BRAF mutations in Langerhans cell histiocytosis
- (2010) G. Badalian-Very et al. BLOOD
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
- (2010) J. A. Ellerhorst et al. CLINICAL CANCER RESEARCH
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
- (2010) P J Mishra et al. ONCOGENE
- Ral activation promotes melanomagenesis
- (2010) P A Zipfel et al. ONCOGENE
- Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma
- (2009) Lars A. Akslen et al. MELANOMA RESEARCH
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- OncogenicNRAShas multiple effects on the malignant phenotype of human melanoma cells culturedin vitro
- (2008) Malihe Eskandarpour et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now